PNC Financial Services Group
AIMT

PNC Financial Services Group’s Aimmune Therapeutics AIMT Stock Holding History

PNC Financial Services Group’s Portfolio AIMT Stock Details AIMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-212
Closed -$7K – 4175
2020
Q3 		$7K Buy
+212
New +$4.51K ﹤0.01% 3618
2019
Q4 		– Sell
-128
Closed -$3K – 4176
2019
Q3 		$3K Hold
128
– – ﹤0.01% 3833
2019
Q2 		$3K Buy
+128
New +$2.63K ﹤0.01% 3841
2018
Q2 		– Sell
-32
Closed -$2K – 4336
2018
Q1 		$2K Hold
32
– – ﹤0.01% 4082
2017
Q4 		$2K Buy
+32
New +$1.03K ﹤0.01% 4043

PNC Financial Services Group's AIMT Position: Q4 2020 in Review

PNC Financial Services Group sold out of Aimmune Therapeutics (AIMT) in Q4 2020, closing a stake of 212 shares — an estimated $7K sold.

PNC Financial Services Group first reported a position in AIMT in Q4 2017 and held it in 5 quarters. The position peaked at $7K in Q3 2020. 0 funds tracked by Wall St. Rank hold AIMT as of Q4 2020.

  • PNC Financial Services Group reported no remaining Aimmune Therapeutics position as of Q4 2020 after selling out during the quarter.
  • PNC Financial Services Group sold 212 Aimmune Therapeutics shares in Q4 2020, an estimated $7K.
  • PNC Financial Services Group first reported a position in Aimmune Therapeutics in Q4 2017 and held it in 5 quarters.
  • PNC Financial Services Group's Aimmune Therapeutics position peaked at $7K in Q3 2020.
  • 0 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2020.

Based on PNC Financial Services Group's 13F filing for Q4 2020, filed 12 Feb 2021.